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http://www.biomedcentral.com/1471-2407/14/282RESEARCH ARTICLE Open AccessHepatitis B spliced protein (HBSP) promotes the
carcinogenic effects of benzo [alpha] pyrene by
interacting with microsomal epoxide hydrolase
and enhancing its hydrolysis activity
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Background: The risk of hepatocellular carcinoma (HCC) increases in chronic hepatitis B surface antigen (HBsAg)
carriers who often have concomitant increase in the levels of benzo[alpha]pyrene-7,8-diol-9,10-epoxide(±)
(BPDE)-DNA adduct in liver tissues, suggesting a possible co-carcinogenesis of Hepatitis B virus (HBV) and benzo
[alpha]pyrene in HCC; however the exact mechanisms involved are unclear.
Methods: The interaction between hepatitis B spliced protein (HBSP) and microsomal epoxide hydrolase (mEH) was
confirmed using GST pull-down, co-immunoprecipitation and mammalian two-hybrid assay; the effects of HBSP on
mEH-mediated B[alpha]P metabolism was examined by high performance liquid chromatography (HPLC); and the
influences of HBSP on B[alpha]P carcinogenicity were evaluated by bromodeoxyuridine cell proliferation,
anchorage-independent growth and tumor xenograft.
Results: HBSP could interact with mEH in vitro and in vivo, and this interaction was mediated by the N terminal 47
amino acid residues of HBSP. HBSP could greatly enhance the hydrolysis activity of mEH in cell-free mouse liver
microsomes, thus accelerating the metabolism of benzo[alpha]pyrene to produce more ultimate carcinnogen, BPDE,
and this effect of HBSP requires the intact HBSP molecule. Expression of HBSP significantly increased the formation
of BPDE-DNA adduct in benzo[alpha]pyrene-treated Huh-7 hepatoma cells, and this enhancement was blocked by
knockdown of mEH. HBSP could enhance the cell proliferation, accelerate the G1/S transition, and promote cell
transformation and tumorigenesis of B[alpha]P-treated Huh-7 hepatoma cells.
Conclusions: Our results demonstrated that HBSP could promote carcinogenic effects of B[alpha]P by interacting
with mEH and enhancing its hydrolysis activity.
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Hepatocellular carcinoma (HCC) is the fifth most common
cancer and the third leading cause of cancer death world-
wide [1]. Hepatocarcinogenesis is a slow multistep and
multifactorial process involving a progressive accumulation* Correspondence: linxu@mail.fjmu.edu.cn
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reproduction in any medium, provided the orof changes at gene and protein level [2]. Chronic hepatitis
B virus (HBV) infection is a major risk factor for HCC in
the endemic areas. Several lines of evidences suggested that
a synergistic interaction between environmental carcino-
gens and HBV-carcinogens may play a critical role in the
carcinogenesis of HCC [3,4].
HBV is a small enveloped hepatotropic virus with a par-
tially double-stranded DNA genome of approximately
3.2 kb in length [5]. In addition to the immune response
to the viral proteins, which is considered to play a major
role in the liver disease outcome, some HBV proteins also
directly participate in chronic hepatitis and HCC, amongtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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truncated middle surface protein (MHBst) have been exten-
sively studied [8]. In the past decade, a novel hepatitis B
spliced protein (HBSP) encoded by a 2.2 kb singly spliced de-
fective HBV genome (spliced between positions 2447 nt and
489 nt) has been detected in the liver tissues and the serum
from patients with hepatitis B [9,10]. HBSP has been shown
to play an important role in hepatopathogenesis [11-13], yet
the exact mechanisms remain to be fully elucidated.
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous
environmental pollutants [3], exposure to which causes
many cancers mostly mediating through the PAHs’ react-
ive metabolites, dihydrodiol epoxides [14]. Benzo[α]pyrene
(B[alpha]P) is a best characterized PAH compound and is
considered to be an indirect genotoxin. Its carcinogenic
and mutagenic effects are manifested after being con-
verted in vivo into a vicinal B[alpha]P-7,8-diol-9,10-epox-
ide (BPDE) [15,16]. In male infant mice, exposure to B
[alpha]P induces liver tumors [17]. In addition, epidemico-
logical studies have shown that the risk for developing
HCC increased dramatically in those with the combin-
ation of higher BPDE-DNA adducts and HBV infection
[3,4], suggesting the possible role of HBV-B[alpha]P inter-
action in hepatocarcinogenesis.
Microsomal epoxide hydrolase (mEH) plays a pivotal role
in B[alpha]P conversion by hydration of B[alpha]P-7,8-
oxide to B[alpha]P-7,8-diol, an important intermediate mol-
ecule of B[alpha]P metabolism [18,19]. The critical role of
mEH bioactivation in PAH-induced carcinogenesis was
demonstrated in EPHX1 (coding for mEH) null mice which
were completely resistant to the tumorigenic effects of
dimethylbenz[alpha]anthracene in a complete carcinogen-
esis assay [20]. In our previous study by a yeast two-hybrid
screening [21], mEH was identified as a specific binding
partner for HBSP from a human liver cDNA library. In this
study, complex formation between HBSP and mEH under
both cell-free and intracellular conditions was further con-
firmed, and the effects of HBSP on mEH-mediated B
[alpha]P metabolism and the carcinogenic effects of B
[alpha]P were evaluated. The results demonstrated that
HBSP could promote carcinogenic effects of B[alpha]P by
interacting with mEH and enhancing its hydrolysis activity.
Methods
Plasmid constructs
Vector pCMVTNT-EPHX1 used for in vitro translation of
microsomal epoxide hydrolase (mEH) was constructed by
inserting of EPHX1 gene (GeneBank Accession No.
NM_000120) cDNA into pCMVTNT (Promega, Madison,
WI, USA) between the Xho I and Kpn I sites, EPHX1 gene
cDNA was amplified by reverse transcription polymerase
chain reaction (RT-PCR) from the total RNA isolated
from Huh-7 hepatoma cells. The primers used were: for-
ward primer, 5′- CCGCTCGAGGCCACCATGTGGCTAGAAATCCTCCTCACT-3′; reverse primer, 5′-CGGGG
TACCTCATTGCCGCTCCAGCAC-3′. pACT-EPHX1353–455
coding for 353–455 amino acids of mEH was generated
by an in-frame insertion of PCR amplified fragment
using screened cDNA library prey plasmid as a template
into pACT between the Sal I and Not I sites (encodes a
herpes simplex virus type 1 VP16 protein, Promega). The
primers used were: forward primer: 5′-ACGCGTCGACT
TGACCTGCTGACCAAC-3′; reverse primer: 5′-ATAAG
AATGCGGCCGC TCATTGCCGCTCCAGCAC-3′. pGEX-
HBSP coding for GST-HBSP protein, pBIND-HBSP,
pBIND-HBSP1-47 and pBIND-HBSP48-111, which respec-
tively codes for GAL4 DNA-binding domain fused full
length, N terminal 47 amino acids and C terminal 64 amino
acids of HBSP, were described previously [21].
GST pull-down assay
E. coli Rosetta (DE3) (Novagen, Madison, Wisconsin, USA)
was transformed with pGEX-HBSP, and the expression of
GST-fused HBSP was induced with 0.5 mM isopropy l-
β-D-thiogalactopyranoside (IPTG, Merck, Darmstadt,
Germany) for 3 h at 28°C. The cells were harvested and
suspended in phosphatate-buffered saline (PBS) contain-
ing 5 mM DTT and protease inhibitor cocktail (Roche
Diagnostics, Mannheim, Germany). The cells were then dis-
rupted by sonication. After centrifugation, the glutathione-
Sepharose 4B beads (GE Healthcare, Uppsala, Sweden)
were added to the supernatants and incubated overnight
at 4°C. Then the glutathione-Sepharose 4B beads were
washed three times with PBS containing 5 mM DTT
and protease inhibitor cocktail (Calbiochem, La Jolla,
CA). 35S-Labeled mEH protein was prepared using the
TNT T7 Coupled Reticulocyte Lysate System (Promega)
by adding 2 μg of pCMVTNT-EPHX1 and 50 μCi of
35S-methionine (Amersham Pharmacia Biotech, Piscataway,
NJ, USA). For GST pull-down assay, 35S-labeled mEH was
added to the GST recombinant proteins and glutathione-
Sepharose 4B beads, and incubated overnight at 4°C.
Beads were washed three times with 1% Triton X-100 in
PBS, re-suspended and subjected to 12% sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).
The presence of 35S-mEH was detected by autoradiography.
Co-immunoprecipitation (Co-IP) assay
A total of 4 × 106 Huh-7 hepatoma cells in a 10 cm dish
were transfected with 12 μg each of the constructs
pBIND-HBSP, pBIND-HBSP1–47, pBIND-HBSP48–111 or
pBIND. Forty-eight hours after transfection, the cells
were washed three times with PBS and lysed using RIPA
lysis buffer (Pierce, Rockford, IL, USA) containing a pro-
teinase inhibitor cocktail (Roche Diagnsotics). The so-
luble proteins were pre-cleared with 100 μL of a 50%
slurry of protein A agarose (Invitrogen, Carlsbad, CA,
USA), and then the clear lysates were mixed with 2 μg
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ogy, Santa Cruz, CA, USA) and 100 μL of a 50% slurry of
protein A agarose. The immunoprecipitated complexes
were washed with lysis buffer and then analyzed by 12%
SDS-PAGE and western blot, using specific antibodies
including anti-GAL4BD monoclonal antibody (1:4000 di-
lution, Clontech, Palo Alto, CA, USA) and anti-mEH anti-
body (1:200 dilution, Santa Cruz Boitechnology).
Mammalian two-hybrid assay
CheckMate Mammalian Two-Hybrid System (Promega)
was used following the manufacturer’s instructions. Briefly,
Huh-7 hepatoma cells (106 cells per 6 cm dish) were co-
transfected with pACT-EPHX1353–455 and pBIND-HBSP,
pBIND-HBSP1–47 or pBIND-HBSP48–111 vector with the
pG5luc as a reporter plasmid, using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions.
Paired empty plasmids pBIND and pACT were used as
negative controls. At 48 h post-transfection, the cells were
harvested and renilla-normalized firefly luciferase activities
were measured using the Dual-Luciferase Reporter Assay
System (Promega) following the manufacturer’s instruc-
tions. The relative luciferase activities were obtained by
comparison to the negative controls (pBIND and pACT),
which were set to 1 in each experiment. Each transfection
was performed three times, and each time in duplicate. The
relative luciferase activities are presented as mean ± SD.
Recombinant adenoviruses preparation
Recombinant adenoviruses were generated by using
AdEasy XL System (Stratagene, La Jolla, CA, USA) fol-
lowing the manufacturer’s instruction. Briefly, plasmid
pShuttle-IRES-hrGFP-1-HBSP was generated by insert-
ing HBSP gene into the vector pShuttle-IRES-hrGFP-1.
HBSP-expressing (pAdHBSP) or control (pAdControl) re-
combinant adenoviral vectors were then generated by
homologous recombination of pAdEasy-1 and pShuttle-
IRES-hrGFP-1-HBSP or pShuttle-IRES-hrGFP-1 in E. coli
BJ5183-AD-1. The colonies obtained were screened for
appropriate recombination events by Pac I restriction
endonuclease analyses. The pAdHBSP and pAdControl
were then digested with Pme I and used to transfect
the 293A packaging cell line (Invitrogen) to produce
HBSP-expressing (HBSP-Ad) and control (GFP-Ad) re-
combinant adenoviruses. Exponentially growing Huh-7
hepatoma cells were infected with these recombinant
adenoviruses at a multiplicity of infection (MOI) of
100. This dose of virus was sufficient to give 100% in-
fectivity as determined by GFP expression under fluo-
rescence microscopy.
Analysis of effects of HBSP on styrene oxide (STO) hydrolysis
4 μg of mouse liver microsomal protein (Sigma, St. Louis,
MO, USA) was incubated with 40 or 100 μg of bacteriallyexpressed NUS-StrepII-tagged HBSP, HBSP1–47 (N ter-
minal 47 amino acids of HBSP), HBSP48–111 (C terminal
64 amino acids of HBSP) or Nus-StrepII (negative control)
[21] for 20 min at 37°C. After incubation, the reaction was
initiated by adding 400 μL of 0.1 M potassium phosphate
buffer (pH7.4) and 1 mM of STO (Sigma). Then the mix-
ture was incubated for 20 min at 37°C. The reaction was
terminated by adding 1 mL of cold ethyl acetate. The
mixtures were measured by high performance liquid chro-
matography (HPLC) as described before [22]. The STO
was identified by comparison of their retention times
with co-injected authentic standards of STO, and quanti-
fied by integrating the areas under the peaks. The assay
was performed three times, and the results were expressed
as mean ± SD.
Analysis of effects of HBSP on B[alpha]P metabolism
4 μg of mouse liver microsomal protein was incubated with
40 or 100 μg of StrepII-tagged HBSP, HBSP1–47, HBSP48-111
or NUS-StrepII (negative control) for 20 min at 37°C.
After incubation, the reaction was initiated by adding
200 μL of 0.1 M potassium phosphate buffer (pH7.4),
10 μM NADPH (Sigma) and 0.5 μM of B[alpha]P (Sigma).
Then the mixtures were incubated for 20 min at 37°C. The
reaction was terminated by adding 1 mL of cold ethyl acet-
ate. The mixtures were measured by HPLC as previously
described [23]. The B[alpha]P metabolites were identified
by comparing their retention times with co-injected au-
thentic standards of B[alpha]P and B[alpha]P-7,8-diol-9,10-
epoxide (BPDE) and were quantified by integrating the
areas under the peaks. B[alpha]P overall metablic turnover
was expressed as percentage of initial substrate concentra-
tion. The analyses were performed three times, and the re-
sults were expressed as mean ± SD.
Cell culture and B[alpha]P exposure
Huh-7 hepatoma cells were cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM, Invitrogen) supplemented
with 10% fetal bovine serum (FBS, Invitrogen). 5 × 105
Huh-7 hepatoma cells were infected with 100 MOI of re-
combinant adenoviruses GFP-Ad and HBSP-Ad, respect-
ively. 72 hours after the infection, the cells were treated
with 1 μM of B[alpha]P for 24 h, and used for detection
of cellular BPDE-DNA by immunocytochemistry. Cells used
for assay of proliferation, cell cycle, transformation and
tumorigenicity were prepared by viral infection and continu-
ously treated with 1 μM of B[alpha]P for 4 weeks (10 pas-
sages), then the cells were harvested and kept at −80°C until
use. These cells were designated as Huh-7/HBSP/B[alpha]
P (Huh-7 hepatoma cells infected with HBSP-Ad and treated
with B[alpha]P), Huh-7/GFP/B[alpha]P (Huh-7 hepatoma
cells infected with GFP-Ad and treated with B[alpha]P),
Huh-7/HBSP (Huh-7 hepatoma cells infected with HBSP-
Ad and without treating by B[alpha]P) or Huh-7/GFP
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RNA interference assay
100 pmol of either small interfering RNA targeting mEH
(mEH siRNA, Santa Cruz Biotechnology) or negative con-
trol was used for transfection by lipofectamine RNAiMAX
reagent (Invitrogen) in accordance with the manufac-
turer’s instructions. The cells were collected using RIPA
lysis buffer (Pierce) 48 h after transfection. The protein
concentration was measured with a BCA Protein Quant
Kit (Bio-Rad, Hercules, CA, USA).
Western blotting analysis
A total of 30 μg protein was subjected to 12% SDS-
PAGE, and then electrophoretically transferred to a
polyvinylidene fluoride (PVDF) membrane (Millipore,
Billerica, MA, USA). Protein blots were incubated separ-
ately with a panel of specific antibodies such as anti-mEH
(1:500 dilution, Santa Cruz Biotechnology) and anti-β-actin
(1:4000 dilution, Sigma). An alkaline phosphatase (AP)-
conjugated goat anti-mouse IgG was used as a secondary
antibody. CDP-Star reagent (Roche Diagnostics) was used
for color development.
Immunocytochemistry assay of BPDE-DNA
The procedure was performed as previously described [24].
Briefly, when the cells on sterilized glass coverslips reached
70-80% confluence, they were fixed with 4% paraformalde-
hyde in PBS, and permeabilized with 0.2% Triton X-100 in
PBS. After incubation with anti-BPDE-DNA (1:50 dilution,
Santa Cruz), the cells were incubated with a biotinylated
secondary antibody followed by streptavidin conjugated
with horseradish peroxidase (HRP) for 10 min. The immu-
noreaction was visualized using 3-3′ diaminobenzidine
tetrachloride (DAB, Santa Cruz). The slides were mounted
with Eukitt (Sigma) and observed with an Olympus BX60
microscope. Images were captured with Image-Pro Express
6.0 (IPE6.0) software.
Bromodeoxyuridine cell proliferation assay
Huh-7/HBSP/B[alpha]P, Huh-7/GFP/B[alpha]P, Huh-7/
HBSP or Huh-7/GFP were seeded triplicate in 96-well
plates at 2 × 103/well. Cell proliferation was determined
daily for 9 days by bromodeoxyuridine (BrDU) assay ac-
cording to the manufacturer’s instructions. Briefly, after
the cells were plated and serum-starved for 24 hours,
BrDU was added to each well at a dilution of 1:2000 and
the cells incubated for an additional 24 h. The BrDU in-
corporation (a measure of DNA synthesis and growth)
was measured by using the BrDU Cell Proliferation assay
kit (CalBiochem, San Diego, CA, USA) at 450 nm using
a microplate reader. The assay was performed three
times, and the results were expressed as mean ± SD.Cell cycle analysis
Huh-7/HBSP/B[alpha]P or Huh-7/GFP/B[alpha]P were
seeded in 6-well plates at 1 × 104/well and serum-starved
with 0.5% FBS DMEM for 24 h. Cells were harvested
after serum starvation at day 2, 4, and 6 days. Cells were
fixed with ice-cold 70% ethanol (pre-chilled at −20°C),
washed with PBS (pH 7.2), incubated with 0.05 mg/mL
propidium iodide (PI, Sigma) and 1 μg/mL RNase A at
37°C for 30 min in dark. The DNA content of 10,000
cells was analyzed by flow cytometry (Beckman Coulter,
Miami, Florida, USA) and CXP 2.2. software. The per-
centage of each phase of the cell cycle was determined.Anchorage-independent growth in soft agar
The assay was performed as previously described [25].
Briefly, 2 × 103 Huh-7/HBSP/B[alpha]P or Huh-7/GFP/B
[alpha]P were suspended in 0.3% agarose in DMEM sup-
plemented with 10% FBS, and plated in 60 mm dishes
over a basal layer of 0.6% agarose in the same medium.
All dishes were incubated at 37°C in a 5% CO2 humidi-
fied atmosphere, and were examined microscopically for
colony formation after a 2-week incubation.Tumor xerograft
All the procedures involving animals were approved by
Experimental Animal Ethics Committee, Fujian Medical
University. The method was used as previously described
[26] with minor changes. Briefly, the right flanks of BALB/c
nude mice (nu/nu) (male, 4 weeks old) were inoculated
subcutaneously with pooled 2 × 106 of Huh-7/HBSP/B
[alpha]P or Huh-7/GFP/B[alpha]P in 0.2 mL PBS per ani-
mal. Tumor size was measured every 3 days, and the tumor
volume was calculated by using the following formula:
(length ×width2)/2. After 21 days of inoculation, all mice
were sacrificed, tumors were dissected out, weighted, and
processed for immunohistochemistry.Immunohistochemistry
Tissues were fixed in 4% neutral buffered formalin, proc-
essed, then embedded in paraffin and cut into 5 μm sec-
tions. Tissues sections were deparaffinized and rehydrated.
Endogenous peroxidase were blocked with 10 min incuba-
tion in 3% H2O2 in PBS. After blocking of non-specific
sites with 1.5% blocking serum in PBS for 1 h at room
temperature (RT), tissue sections were incubated 1 h at
RT with the anti-BPDE-DNA. After a 30 min reaction
with a biotinylated secondary antibody, slides were washed
with PBS and incubated with streptavidin conjugated with
HRP for 10 min. The reaction was then revealed with
DAB. Then the slides were mounted with Eukitt and ob-
served with an Olympus BX60 microscope. Images were
captured with IPE6.0 software.
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In vitro and In vivo interaction between HBSP and mEH
A GST pull-down assay was performed to confirm the
direct interaction between recombinant HBSP and re-
combinant mEH in vitro. The result showed that the
recombinant GST fusion proteins were well expressed
and precipitated by glutathione-Sepharose 4B beads
(Figure 1A). GST-HBSP fusion protein complexed with
35S-labeled mEH (Figure 1B).
Co-immunoprecipitation (Co-IP) assays were performed
to examine the intracellular complex formation between
recombinant HBSP and endogenous mEH. As shown in
Figure 1C, endogenous mEH in Huh-7 hepatoma cells ef-
ficiently co-immunoprecipitated with full-length HBSP
and HBSP1–47, but not HBSP48–111 or GAL4BD, indicating
that the mEH-binding site of HBSP is located within the
N-terminal half of the molecule (residues 1–47).
A mammalian two-hybrid system was further employed
to enable an intracellular evaluation of the binding between
HBSP and mEH in Huh-7 hepatoma cells. The results
demonstrated that GAL4BD-tagged HBSP, HBSP1–47 and
HBSP48–111 as well as VP16-tagged mEH353–455 expressed
well in transfected Huh-7 hepatoma cells (Figure 1D). The
luciferase activities (Figure 1E) of Huh-7 hepatoma cells co-
transfected with pACT-mEH353–455 and pBIND-HBSP or
pBIND-HBSP1–47 were significantly higher (~9 fold for
pBIND-HBSP and ~12 fold for pBIND-HBSP1–47) as com-
pared to the negative control (P < 0.01), while the luciferase
activity for the pBIND-HBSP48–111 group was similar to
negative control. The results indicate that HBSP-mEH
binding interaction can be detected within mammalian cells
and that the mEH-binding site of HBSP molecule is again
localized to the N-terminal half.HBSP enhances the hydrolysis activity of mEH
Hydrolysis of the styrene oxide (STO) to styrene glycol
was widely used to evaluate specifically the hydrolysis
activity of mEH in cell free mouse liver microsomes [16].
The results (Figure 2A) showed that hydrolysis of the
STO by mouse liver microsomes in the presence of 40 μg
and 100 μg HBSP was faster than that in NUS-StrepII
(negative control) (105.13 ± 5.62 vs 79.56 ± 4.72 and
134.52 ± 1.66 vs 89.33 ± 13.62, respectively, P < 0.05). In
contrast, as for HBSP1–47 and HBSP48–111, no significant
differences were observed (P > 0.05). These observations
suggest that HBSP can enhance the hydrolysis activity of
mEH, and this effect is dependent on HBSP integrity since
neither HBSP1–47 nor HBSP48–111 was functional.The influence of HBSP on the metabolism of B[alpha]P
in cell-free mouse liver microsomes was also measured.
The results demonstrated that the overall turnover of B
[alpha]P (expressed as% initial substrate concentration)
(Figure 2B) in the presence of 40 μg or 100 μg of HBSP
was higher than that of NUS-StrepII (58.65 ± 1.92 vs
43.49 ± 4.78 and 64.48 ± 1.78 vs 48.56 ± 1.0, respectively,
P < 0.05). In addition, substantially more BPDE (Figure 2C),
was formed in the presence of 40 μg or 100 μg of HBSP as
compared to the negative control (2.79 ± 0.58 vs 1.79 ±
0.24 and 3.65 ± 0.52 vs 1.65 ± 0.47, respectively, P < 0.05).
These results indicated that HBSP could enhance the me-
tabolism of B[alpha]P in cell-free mouse liver microsomes.
The influence of HBSP on B[alpha]P metabolism in liv-
ing cells was further investigated. As shown in Figure 2D,
the Huh-7 hepatoma cells infected with HBSP-Ad exhib-
ited more intense immunostains than control cells, indica-
tive of higher amount of BPDE-DNA adducts within
the nuclei. In addition, when mEH in HBSP-Ad infected
cells was knocked down by specific siRNA (Figure 2E),
the staining intensity was reverted back to the level
similar to the negative control (Figure 2F). These re-
sults indicated that HBSP accelerated the metabolism
of Benzo[alpha]pyrene through interaction with mEH
in Huh-7 hepatoma cells.
HBSP enhances the proliferation of B[alpha]P-treated
Huh-7 hepatoma cells
As shown in Figure 3A and B, Huh-7/HBSP/B[alpha]P
and Huh-7/HBSP could express HBSP and Huh-7/HBSP/
B[alpha]P showed a more intense immunoreactivity for
anti-BPDE-DNA antibody than Huh-7/GFP/B[alpha]P. In
order to investigate the effects of HBSP on the prolifera-
tion of B[alpha]P-treated cells, Huh-7/HBSP/B[alpha]P,
Huh-7/GFP/B[alpha]P or Huh-7/HBSP cells were seeded
and cultured, BrdU assay was performed. The results dem-
onstrated that the proliferation of Huh-7/HBSP/B[alpha]P
increased from day 4 to day 7, and significantly faster than
that of Huh-7/GFP/B[alpha]P, Huh-7/HBSP or Huh-7/GFP
(Figure 3C). These results indicated that HBSP could en-
hance the proliferation of B[alpha]P-treated Huh-7 hepa-
toma cells and that this enhancement is not the result of
HBSP alone directly acting upon Huh-7 but requires the
presence of B[alpha]P.
HBSP induces cell cycle alterations of B[alpha]P-treated
Huh-7 hepatoma cells
It has been reported that the observed increase in the pro-
liferation of cells treated with B[alpha]P was accompanied
by an increased G1/S transition [27,28]. To investigate the
effects of HBSP on the cell cycle in B[alpha]P-treated cells,
cell cycle phase distributions of Huh-7/HBSP/B[alpha]P
and Huh-7/GFP/B[alpha]P were compared at day 2, 4,
and 6 after serum starvation. The results showed that
Figure 1 In vitro and In vivo interaction between HBSP and mEH. (A) Bacterially expressed GST and GST-HBSP recombinant proteins bound
to glutathione-sepharose beads. (B) GST pull-down assay. GST recombinant proteins were incubated with 35S-labeled mEH, immobilized proteins
and subjected to SDS-PAGE and autoradiography. (C) Co-IP assay showing the interaction between HBSP and endogenous mEH in Huh-7
hepatoma cells. Cells were separately transfected with pBIND-HBSP, pBIND-HBSP1–47, or pBIND-HBSP48–111. Cell lysates from transfected cells were
immunoprecipitated with anti-mEH, and the immunoprecipitation complexes were subjected to immunoblotting with anti-GAL4BD (upper) or
anti-mEH (lower). (D) Western blot analysis of full-length and truncated HBSP, expressed as a fusion protein, with GAL4 DNA binding domain (left).
mEH353-455 expressed as a fusion protein, with VP16 activation domain in Huh-7 hepatoma cells (right). (E) Mammalian two-hybrid assay. HuH-7
cells were lysed 48 h after transfection and renilla-normalized firefly luciferase activity was determined using the dual luciferase assay system.
Data are presented as means ± SD for three independent experiments. The firefly luciferase expression is given as folds over the background
(set arbitrarily at 1). (* P < 0.01).
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in cell cycle phase distribution with a decrease in the frac-
tion of the cells in G1 phase and a corresponding in-
crease in the fraction of the cells in S phase (Figure 4).
The percentage of S phase in Huh-7/HBSP/B[alpha]P was
45.99%, 57.95% and 58.14% for 2, 4 and 6 day, respectively,
significantly higher than those of Huh-7/GFP/B[alpha]P
(37.74%, 42.94% and 48.95%, respectively). These data
showed that HBSP increased G1/S transition of B[alpha]
P-treated Huh-7 hepatoma cells.
HBSP enhances anchorage-independent growth of B
[alpha]P-treated Huh-7 hepatoma cells in soft agar
To investigate whether HBSP affects the transformation of
B[alpha]P-treated Huh-7 cells, the anchorage-independent
growth in soft agar was performed. The results revealed that
Huh-7/HBSP/B[alpha]P grew significantly better than the
control of Huh-7/GFP/B[alpha]P in soft agar (Figure 5A).
Moreover, Huh-7/HBSP/B[alpha]P cells showed a dramaticincrease in the number of the colonies in soft agar than
Huh-7/GFP/ B[alpha]P (Figure 5B). These data indicate that
HBSP enhances malignant transformation of B[alpha]P-
treated Huh-7 hepatoma cells.
HBSP enhances tumor development of B[alpha]P-treated
Huh-7 hepatoma cells in nude mice
To test the effect of HBSP on tumorigenicity of B[alpha]
P-treated Huh-7 cells, nude mice were inoculated with
Huh-7/HBSP/B[alpha]P or Huh-7/GFP/B[alpha]P. All of
the mice inoculated with the Huh-7/HBSP/B[alpha]P de-
veloped visible tumors within 9 days after the injection,
while only six of eight (75%) mice inoculated with Huh-
7/GFP/B[alpha]P developed visible tumors on day 15
post-injection. After the mice were sacrificed on day 21
post inoculation (Figure 6A), the xenografts were dis-
sected out (Figure 6B). The volume and weight of the xe-
nografts were measured, and the presence of BPDE-DNA
in the xenografts was detected. The results demonstrated
Figure 2 Effects of HBSP on the hydrolysis activity of mEH. (A) Effects of HBSP on the hydrolysis of STO. STO was analyzed by HPLC and
quantified. The experiments were performed for three times (* P < 0.05). (B-C) Effects of HBSP on the metabolism of B[alpha]P. B[alpha]P and
BPDE were analyzed by HPLC and quantified. The B[alpha]P overall metabolic turnover was expressed as% initial substrate concentration. The
experiments were performed for three times. (* P < 0.05). (D-F) Effects of HBSP on the mEH-dependent BPDE-DNA adduct formation in Huh-7
hepatoma cells. After GFP-Ad or HBSP-Ad infected Huh-7 hepatoma cells were treated with B[alpha]P, cells were submitted for immunocytochemistry
assay using anti-BPDE-DNA. Images were taken at × 400 magnification (D) After treating with mEH-siRNA and exposed to B[alpha]P, expression
level of mEH in Huh-7 hepatoma cells were evaluated by western blot (E) and intracellualr BPDE-DNA level was detected by Immunocytochemistry
assay. Images were taken at × 400 magnification (F).
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xenografts derived from the Huh-7/HBSP/B[alpha]P as
compared to that in the xenografts from Huh-7/GFP/B
[alpha]P (Figure 6C). In addition, xenografts derived from
the Huh-7/HBSP/B[alpha]P cells were significantly larger
and heavier compared to the those from the Huh-7/GFP/
B[alpha]P cells (xenografts volume: 1861 ± 120 mm3 vs
222 ± 98 mm3; xenografts weight: 1.69 ± 0.28 g vs 0.08 ±
0.04 g, P < 0.01) (Figure 6D and E). These data suggest
that HBSP enhances tumor development of B[alpha]P-
treated Huh-7 hepatoma cells, and this enhancement of
HBSP is accompanied by the formation of more BPDE-
DNA adducts in the tumor cells.
Discussion
Virus-chemical interactions as mechanisms of carcinogen-
esis have been proposed based on epidemiological investi-
gations. For example, tar-based carcinogens generated from
lysol virgin dunching, cigarette smoking, or cooking over
burning wood were co-carcinogens for human papillomavi-
rus (HPV) types 16 and 18 in cervical cancer [29-33].Nitrite inhalants and aluminosilicates were considered as
co-carcinogens for human herpes virus type 8 (HHV-8) in
oncogenesis of human immunodeficiency virus (HIV)-asso-
ciated Kaposi’s sarcoma (KS) [34,35]. Hepatocarcinogenesis
involves a complex interplay of viral, environmental,
and host factors. Long incubation period between the
time of initial HBV infection and the onset of HCC sug-
gests that HBV plays a role in liver oncogenesis as a cofac-
tor or tumor promoter rather than a direct cause of
cancer [36-38]. In fact, the crucial role of hepatocarcino-
gen diethylnitrosamine in the tumor development of HBx
transgenic mice [39], and the synergistic interactions be-
tween HBV and aflatoxins or alcohol in HCC have been
well documented [40,41]. In the present study, HBV-B
[alpha]P interaction in hepatocarcinogenesis was further
confirmed and the mechanisms explored.
B[alpha]P is a major toxicant in diesel exhaust, charcoal-
broiled food, industrial waste byproducts, and cigarette
smoke [42,43]. Administration of B[alpha]P by different
routes has been shown to result in the production of tu-
mors in several species of animals [44,45]. The metabolic
Figure 3 Effects of HBSP on the proliferation of B[alpha]P-treated Huh-7 hepatoma cells. (A) HBSP expression in Huh-7/HBSP/B[alpha]P,
Huh-7/GFP/B[alpha]P or Huh-7/HBSP. 30 μg of cellular proteins were subjected to 12% SDS-PAGE, transfered to a PVDF membrane, and probed
with anti-mEH. β-actin served as a loading control. (B) Detection of BPDE-DNA in Huh-7/HBSP/B[alpha]P, Huh-7/GFP/B[alpha]P or Huh-7/HBSP
cells. Cells on sterilized glass coverslips were detected for BPDE-DNA by immunocytochemistry assay. Images were taken at × 400 magnification.
(C) Cell proliferation of Huh-7/HBSP/B[alpha]P, Huh-7/GFP/B[alpha]P, Huh-7/HBSP or Huh-7/GFP cells. Cells were seeded in 96-well plates at
2 × 103/well, cell proliferation was determined daily in triplicate for 9 days by BrdU assay. The optical density (OD) was measured at 450 nm
using a microplate reader. The analyses were repeated three times, and the results were expressed as mean ± SD.
Figure 4 Effects of HBSP on cell cycle alterations of B[alpha]
P-treated Huh-7 hepatoma cells. 1 × 104 of Huh-7/HBSP/B[alpha]P
or Huh-7/GFP/B[alpha]P cells in 6 well plates were serum-starved for
24 h, the cells were harvested at the time of 2, 4, and 6 days after
serum starvation. Cells were fixed with ice-cold 70% ethanol (prechilled
at −20°C), washed with PBS, incubated with 0.05 mg/ml PI and
1 μg/ml RNase A at 37°C for 30 min in the dark. The DNA content
of 10,000 cells was detected by flow cytometry and analyzed by
CXP 2.2. software. The percentage of each phase of the cell cycle
was determined. The results were one representative data from
three independent experiments.
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tial enzymatically catalyzed reactions including monooxy-
genation by cytochrome P450 (CYP) enzymes, hydration
by mEH and a second CYP-catalyzed oxidation to gener-
ate a carcinotoxic ultimate product, BPDE [46], which is
capable of binding covalently to DNA in the living cells to
form adducts [16]. In the present study, it was demon-
strated that HBSP generated by a 2.2 kb singly-spliced
HBV pre-genomic RNA could specifically bind to the C-
terminal region (amino acid residues 353–455) of mEH,
and resulted in an increase in the hydrolysis activity of
mEH, as demonstrated by hydrolysis assay using STO,
an artificial substrate. In addition, it was also demon-
strated that HBSP could accelerate B[alpha]P metabolism
in mouse liver microsomes leading to an increased amount
of BPDE-DNA adducts. In Huh-7 hepatoma cells, ex-
pression of HBSP resulted in an increased formation of
BPDE-DNA adducts, and this enhancement effect could
be blocked when mEH was knocked down by siRNA,
implicating an indispensable mechanistic role that mEH
plays in the enhancement. HBSP begins at the HBV
polymerase start codon and contains the first 47 amino
acids residues of polymerase (Met1-Asn47, HBSP1–47),
followed by the 64 amino acids residues (Glu48-Tyr111,
HBSP48–111) resulting from a frameshift event [10,21].
More importantly, nucleotide sequence alignment comparison
Figure 5 Effects of HBSP on anchorage-independent growth of B[alpha]P-treated Huh-7 hepatoma cells in soft agar. (A) Huh-7/HBSP/
B[alpha]P or Huh-7/GFP/ B[alpha]P cells grown in soft agar 14 days after plating. Images on left were taken at × 40 magnification. Images
on the right were × 100 magnified and images of the boxed sections depicted on the left. (B) The number of colonies grown in the soft
agar. (* P < 0.05).
Chen et al. BMC Cancer 2014, 14:282 Page 9 of 11
http://www.biomedcentral.com/1471-2407/14/282among the eight (A-H) known genotypes of HBV
showed that the sequence following the 5′-splice site at
nucleotide 2447 and that following the 3′-splice site at
nucleotide 489 are highly conserved (data not shown),
suggesting that generation and function of HBSP areFigure 6 Effects of HBSP on tumorigenicity of B[alpha]P-treated Huh-
with either the Huh-7/HBSP/B[alpha]P or Huh-7/GFP/B[alpha]P. Tumor size
inoculation. (A) The resulting tumors photographed on the 21st day after i
BPED-DNA in tumor tissues detected by immunohistochemistry assay. Imag
out from the sacrificed mice (* P < 0.01). (E) Tumor volume during growth,HBV genotype-independent. In this study, it was shown
that while HBSP-mEH complex formation was medi-
ated by N terminal 47 amino acid residues of HBSP, the
enhancement of mEH activities requires the intact
HBSP molecule.7 hepatoma cells in nude mice. BALB/c nude mice were inoculated
was measured every 3 days. All mice were sacrificed after 21 days of
noculation. (B) The tumors dissected out from the sacrificed mice. (C)
es were taken at × 400 magnification. (D) Weights of tumors dissected
results were expressed as mean ± SD.
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phase to S phase and induces cell proliferation in human
embryo lung fibroblasts (HELF). This effect was medi-
ated by c-Jun activation by PI-3 K/Atk/ERK signaling
pathway with the up-regulation of expression of cyclin
D1, E2F1 and pRb [47]. Moreover, BPDE has been docu-
mented to promote cell transformation and tumorigen-
esis through the induction of cyclin D1 via the PI-3 K
/Akt/MAPK and p70s6k-dependent pathway [48]. Re-
cently, interaction of HBSP with CTSB was found to
promote hepatoma cell motility and invasion, the mech-
anisms involve the secretion and activation of proteolytic
enzymes, increased tumor-induced angiogenesis, and ac-
tivation of the MAPK/Akt signaling [49]. In the present
study, it was demonstrated that HBSP could enhance the
cell proliferation, accelerate the G1/S transition, and pro-
mote cell transformation and tumorigenesis of B[alpha]P-
treated Huh-7 hepatoma cells. These results suggest the
co-carcinogenesis of HBSP and B[alpha]P in HCC, and
shed a new light for potential therapeutic intervention to
prevent hepatocarcinogenesis in the hepatitis B patients
with high B[alpha]P exposure by mEH and/or HBSP
suppression treatment.
Conclusions
In summary, the results of this study demonstrate that
HBSP promotes carcinogenic effects of B[alpha]P through
enhancing the hydrolysis activities of mEH, thereby acceler-
ating the conversion of B[alpha]P to BPDE and increas-
ing the formation of BPDE-DNA adducts while the
physiological significance of HBSP remains to be verified
by comparing full-length HBV (capable of replication and
expression of all the viral proteins at appropriate ratios)
with a mutant incapable of splicing or expression of the
intact HBSP. These findings not only broaden the know-
ledge of virus-chemical interactions in co-carcinogenesis
of HCC, may also lead to the further study of chemopre-
vention of HBV-associated HCC.
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